Ivy shares what a typical day is like for her as a staff nurse in The Royal Marsden's West Wing Clinical Research Centre.

It's been ten years since the Centre for Molecular Pathology (CMP) opened in Sutton, bringing together researchers from The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, under one roof.

A new genetically engineered virus has delivered a one-two punch against advanced cancers in initial findings from a phase I trial.

ESMO Translational Research Award winner, Dr Samra Turajilic, gives insight on what it was like to work on cancer research at the start of the COVID-19 pandemic and the impetus behind the CAPTURE study.

Radiotherapy to the prostate alongside standard treatment can keep some men with advanced prostate cancer alive for longer without detriment to quality of life, long-term study results confirm.

A combination treatment of immunotherapy with the experimental drug guadecitabine may reverse a cancer’s resistance to immunotherapy – making it sensitive to treatment again, a new study has found.

177Lu-PSMA-617, a highly targeted radioactive drug, has been approved by the medicines regulator, the MHRA, for some patients with advanced prostate cancer.

Robotic surgery can improve survival rates and reduce recovery time for some people with recurrent head and neck cancers, suggests a pioneering new international study led by researchers at The Royal Marsden NHS Foundation Trust.

Olaparib, a drug developed through research carried out by scientists and clinicians at The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust, has been approved in Europe for people with high-risk, early-stage breast cancer who have inherited faults in their BRCA1 or BRCA2 genes.

Giving people with bladder cancer chemotherapy and radiotherapy at the same time helps stop cancer from coming back, long-term results of a 10-year study confirm.